Geoffrey Porges
Stock Analyst at Leerink Partners
(1.51)
# 3,423
Out of 5,182 analysts
114
Total ratings
47.37%
Success rate
-1.91%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geoffrey Porges
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Maintains: Outperform | $36 → $49 | $23.70 | +106.75% | 9 | Mar 2, 2026 | |
| PFE Pfizer | Maintains: Market Perform | $52 → $56 | $27.19 | +105.96% | 10 | Dec 15, 2021 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $798 → $850 | $753.93 | +12.74% | 16 | Nov 5, 2021 | |
| HALO Halozyme Therapeutics | Maintains: Outperform | $50 → $48 | $68.05 | -29.46% | 2 | Nov 3, 2021 | |
| AMGN Amgen | Maintains: Market Perform | $234 → $216 | $348.22 | -37.97% | 12 | Nov 3, 2021 | |
| ABBV AbbVie | Maintains: Outperform | $142 → $135 | $208.42 | -35.23% | 16 | Nov 1, 2021 | |
| ROIV Roivant Sciences | Initiates: Outperform | $11 | $29.39 | -62.57% | 1 | Nov 1, 2021 | |
| GILD Gilead Sciences | Maintains: Outperform | $77 → $75 | $139.77 | -46.34% | 14 | Oct 29, 2021 | |
| SNY Sanofi | Upgrades: Outperform | n/a | $48.02 | - | 2 | Sep 27, 2021 | |
| TBPH Theravance Biopharma | Maintains: Outperform | $29 → $10 | $16.64 | -39.90% | 9 | Sep 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $170 → $175 | $441.70 | -60.38% | 9 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $96 → $84 | $29.81 | +181.78% | 3 | May 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $57.81 | - | 1 | Mar 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $61 | $7.59 | +703.69% | 2 | Nov 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $180.54 | - | 8 | Mar 16, 2017 |
Arcus Biosciences
Mar 2, 2026
Maintains: Outperform
Price Target: $36 → $49
Current: $23.70
Upside: +106.75%
Pfizer
Dec 15, 2021
Maintains: Market Perform
Price Target: $52 → $56
Current: $27.19
Upside: +105.96%
Regeneron Pharmaceuticals
Nov 5, 2021
Maintains: Outperform
Price Target: $798 → $850
Current: $753.93
Upside: +12.74%
Halozyme Therapeutics
Nov 3, 2021
Maintains: Outperform
Price Target: $50 → $48
Current: $68.05
Upside: -29.46%
Amgen
Nov 3, 2021
Maintains: Market Perform
Price Target: $234 → $216
Current: $348.22
Upside: -37.97%
AbbVie
Nov 1, 2021
Maintains: Outperform
Price Target: $142 → $135
Current: $208.42
Upside: -35.23%
Roivant Sciences
Nov 1, 2021
Initiates: Outperform
Price Target: $11
Current: $29.39
Upside: -62.57%
Gilead Sciences
Oct 29, 2021
Maintains: Outperform
Price Target: $77 → $75
Current: $139.77
Upside: -46.34%
Sanofi
Sep 27, 2021
Upgrades: Outperform
Price Target: n/a
Current: $48.02
Upside: -
Theravance Biopharma
Sep 16, 2021
Maintains: Outperform
Price Target: $29 → $10
Current: $16.64
Upside: -39.90%
Jul 30, 2021
Maintains: Underperform
Price Target: $170 → $175
Current: $441.70
Upside: -60.38%
May 10, 2021
Maintains: Market Perform
Price Target: $96 → $84
Current: $29.81
Upside: +181.78%
Mar 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $57.81
Upside: -
Nov 28, 2018
Initiates: Outperform
Price Target: $61
Current: $7.59
Upside: +703.69%
Mar 16, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $180.54
Upside: -